# NCT02912559 (NCT02912559)

> Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02912559
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Colon Adenocarcinoma; DNA Repair Disorder; Lynch Syndrome; Stage III Colon Cancer AJCC v8
- Interventions: Atezolizumab; Biospecimen Collection; Computed Tomography; Fluorouracil; Leucovorin Calcium; Magnetic Resonance Imaging; Oxaliplatin; Quality-of-Life Assessment
- Enrollment: 712
- Primary outcome: Disease Free Survival (DFS)

## Commentary we found

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02912559